UK's Hemogenyx Pharmaceuticals H1 loss widens on share-based payments

The UK biopharma firm said its H1 loss widened, driven by a non-cash share-based payment charge. It raised £5.6 million in H1 to fund clinical development of its lead CAR-T therapy.